Alternative Payment Models

This article explores the congruence between payer patient assignment and quality performance and the implications for incentive payments in alternative payment models.

Ishwaria Subbiah, MD, of SCRI Oncology Partners, discusses new findings presented at ASCO 2024. This interview will appear in the annual ASCO recap issue of Evidence-Based Oncology.

While adopting new payment models can come with challenges, there are strategies that can help oncology practices optimize their approaches, said Kathy Oubre, MS, CEO of Pontchartrain Cancer Center.

Coverage from The US Oncology Network Payer Transformation Summit, held September 27-29, 2023, in Atlanta, Georgia.

The single-center study evaluated patients across multiple cancers to understand the utilization, safety, and financial outcomes of bevacizumab-awwb vs reference bevavizumab.

At AHIP 2022, Vanessa Bobb, MD, PhD, FAPA, vice president of Behavioral Health & Medical Integration at CDPHP, moderated a session on real-world study findings showcasing cost and quality benefits of value-based contracting in behavioral health. Bobb discusses findings of the study and how value-based programs can be better leveraged in mental health and substance abuse care.

There are an increasing number of targeted therapies in oncology, but challenges around biomarker testing and treatment selection remain.

Developing alternative payment models for commercial populations in specialties such as oncology is rife with practical challenges. Leading payers and practices share lessons to date.

How Value-based Care Is Changing Radiation Oncology for the Better

The changes come as Tennessee Oncology must now plan for a gap between the Oncology Care Model and a future alternative payment model from CMS.

The Biosimilars Initiative in British Columbia, Canada, mandated patients with certain conditions on the province’s prescription coverage plan to switch from originator etanercept to a biosimilar.

Synthesis of multistakeholder perspectives from a mixed-methods study identifies guiding characteristics for outcomes-based quality measures in future, more patient-centered alternative payment models.

With the ongoing coronavirus disease 2019 pandemic, a rising number of uninsured Americans, and a new Democratic president and Senate majority, 2021 is shaping up to be a dynamic year for health care policy.

A panel at Patient-Centered Oncology Care® 2020 discussed the challenges of a pandemic as oncology practice transformation initiatives continue on.

The coronavirus disease 2019 (COVID-19) pandemic is going to test the new risk adjustment in the Oncology Care Model as patients delay care, said Mike Fazio, senior vice president of Client Services at Archway Health.

There is a lot of uncertainty among providers participating in federal alternative payment models (APMs) given the general election and the upcoming Supreme Court case on the Affordable Care Act (ACA).

A discussion of the final Radiation Oncology Model; after this article went to press, CMS announced a delay until July 2021, reflecting concerns of radiation oncologists.

COVID-19 has delayed the transition to Oncology Care First, but the forthcoming model could help.

Bundled payments offer promise as a supplement to existing payment models to promote scaling up of opioid use disorder treatment using buprenorphine.